BR112019001852A2 - composição de cannabis - Google Patents

composição de cannabis

Info

Publication number
BR112019001852A2
BR112019001852A2 BR112019001852-2A BR112019001852A BR112019001852A2 BR 112019001852 A2 BR112019001852 A2 BR 112019001852A2 BR 112019001852 A BR112019001852 A BR 112019001852A BR 112019001852 A2 BR112019001852 A2 BR 112019001852A2
Authority
BR
Brazil
Prior art keywords
cannabis
treating
relates
sleep disorder
extract
Prior art date
Application number
BR112019001852-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Karelis Harry
Gordon Mara
Smith Stewart
Washer Stewart
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019001852(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of BR112019001852A2 publication Critical patent/BR112019001852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112019001852-2A 2016-08-03 2017-08-03 composição de cannabis BR112019001852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
US62/370,304 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
BR112019001852A2 true BR112019001852A2 (pt) 2019-05-07

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001852-2A BR112019001852A2 (pt) 2016-08-03 2017-08-03 composição de cannabis

Country Status (15)

Country Link
US (2) US11779562B2 (https=)
EP (1) EP3493798A4 (https=)
JP (1) JP2019523283A (https=)
KR (2) KR20190035791A (https=)
CN (1) CN109843287A (https=)
AU (4) AU2017307643B2 (https=)
BR (1) BR112019001852A2 (https=)
CA (1) CA3031810A1 (https=)
CL (1) CL2019000270A1 (https=)
CO (1) CO2019001044A2 (https=)
IL (2) IL296008B2 (https=)
MX (1) MX386620B (https=)
PE (1) PE20200726A1 (https=)
SG (1) SG11201900665VA (https=)
WO (1) WO2018023163A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
NZ757591A (en) * 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
AU2018100837B4 (en) * 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
US20210251949A1 (en) * 2018-06-15 2021-08-19 California Cannabinoids Compositions and Methods for Treatment of Narcolepsy and Related Disorders
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
CN118161552A (zh) * 2019-12-19 2024-06-11 史蒂文·罗斯斯坦 富含多酚化合物的提取物以及相关方法
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
IT202000017137A1 (it) * 2020-07-15 2022-01-15 Linnea Sa Estratti di cannabis sativa e loro usi
DK181329B1 (en) * 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor
US20250144122A1 (en) * 2023-11-06 2025-05-08 Roberto Colon-Cruz Scent-Changing Ointment & Method of Making The Same
WO2026010279A1 (ko) * 2024-07-01 2026-01-08 피비엘바이오랩 주식회사 신규 유산균 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) * 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
LT3062606T (lt) * 2013-10-29 2019-07-10 Biotech Institute, Llc Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas
CA2929280A1 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
US10610512B2 (en) * 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
CA2996626A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
MX385464B (es) 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
IL253664B (en) 2015-01-31 2022-09-01 Constance Therapeutics Inc Production method for extracting oil from cannabis and preparations
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
CA3031811A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019526541A (ja) 2016-08-03 2019-09-19 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
AU2018100837B4 (en) 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
SG11202002169TA (en) 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
WO2021248207A1 (en) 2020-06-12 2021-12-16 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
PE20240682A1 (es) 2020-11-06 2024-04-10 Zelira Therapeutics Operations Pty Ltd Tecnologia de encapsulacion de cannabinoides

Also Published As

Publication number Publication date
AU2019253841A1 (en) 2019-11-14
IL264461B1 (en) 2024-05-01
US12239628B2 (en) 2025-03-04
IL264461A (en) 2019-02-28
EP3493798A1 (en) 2019-06-12
US20220347155A1 (en) 2022-11-03
AU2018100923A4 (en) 2018-08-09
US20230414559A1 (en) 2023-12-28
IL296008B1 (en) 2024-05-01
CA3031810A1 (en) 2018-02-08
WO2018023163A1 (en) 2018-02-08
MX386620B (es) 2025-03-19
EP3493798A4 (en) 2020-05-06
CO2019001044A2 (es) 2019-04-30
SG11201900665VA (en) 2019-02-27
MX2019001285A (es) 2019-06-13
JP2019523283A (ja) 2019-08-22
AU2019253841B2 (en) 2021-07-01
IL264461B2 (en) 2024-09-01
AU2018100923C4 (en) 2019-10-31
IL296008A (en) 2022-10-01
AU2017307643A1 (en) 2018-07-05
CL2019000270A1 (es) 2019-10-04
US11779562B2 (en) 2023-10-10
IL296008B2 (en) 2024-09-01
CN109843287A (zh) 2019-06-04
AU2017307643B2 (en) 2019-07-25
KR20190035791A (ko) 2019-04-03
AU2021240297A1 (en) 2021-10-28
AU2021240297B2 (en) 2023-08-24
AU2018100923B4 (en) 2018-09-27
PE20200726A1 (es) 2020-07-21
KR20210013645A (ko) 2021-02-04

Similar Documents

Publication Publication Date Title
BR112019001852A2 (pt) composição de cannabis
MX387442B (es) Composiciones y tratamientos para el trastorno del sueño
BR112019001794A2 (pt) composição de cannabis
CO2018013654A2 (es) Composiciones nasales de cannabidiol
BR112018076114A2 (pt) composições tópicas de apremilast
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
PH12017502375A1 (en) Method of treating inflammation using natural compounds and/or diet
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
CL2021002401A1 (es) Extractos bacterianos estables como fármacos
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112022007998A2 (pt) Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
MX2018000872A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
BR112015032534A2 (pt) usos de composto ou de sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, composições farmacêuticas e métodos para prevenir e/ou tratar encefalopatia traumática crônica ou condição relacionada em indivíduo e para tratar indivíduo com lesão de concussão
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
ECSP20014155A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
AR108792A1 (es) Composiciones que comprenden timolol
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
ECSP16095557A (es) Métodos para tratar infecciones

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.